SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL)
Clinical trials for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL) explained in plain language.
Never miss a new study
Get alerted when new SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL) trials appear
Sign up with your email to follow new studies for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise for rare brain cancer
Disease control Recruiting nowThis study tests a combination of four drugs (PD-1 inhibitor, rituximab, methotrexate, and orelabrutinib) in 50 people with newly diagnosed or relapsed lymphoma that has spread to the brain. The main goal is to see how many patients remain cancer-free one year after treatment. Th…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New drug duo targets Hard-to-Treat brain cancer
Disease control Recruiting nowThis study tests whether combining two drugs, epcoritamab and ibrutinib, is safe for people with central nervous system (CNS) lymphoma that has returned or not responded to treatment. About 26 adults with this rare brain cancer will take part. The main goal is to find the best do…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL)
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
New drug targets Hard-to-Treat blood cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called NX-5948 in adults with certain blood cancers (like CLL or lymphoma) that have come back or stopped responding to treatment. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to find a safe dose …
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 18, 2026 12:09 UTC